Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand
Published 2 months ago
Description
Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.